SCHEMBL1935385

SCHEMBL1935385

CC(C)(C)N(CCc1ccc(CN2CC(O)C2)cc1)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 8/20 0.45
S1PR5 Q9H228 7/20 0.45
S1PR3 Q99500 3/20 0.43
S1PR4 O95977 3/20 0.43
OPRM1 P35372 1/20 0.42
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GRK5 P34947 1/20 0.39
CDK8 P49336 1/20 0.39
MLNR O43193 1/20 0.39
CYP3A4 P08684 1/20 0.39
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM3 P20309 1/20 0.38
FUCA1 P04066 2/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2237887 0.92 S1PR1 (0.45) S1PR1S1PR5S1PR3S1PR4OPRM1
SCHEMBL2236473 0.90 OPRM1 (0.46) S1PR1S1PR5S1PR3S1PR4OPRM1
SCHEMBL2237331 0.88 ALDH1A1 (0.55) OPRM1HTTKDM4EALDH1A1
SCHEMBL2238599 0.87 OPRM1 (0.51) OPRM1MEN1KMT2AKDM4ELMNA
SCHEMBL2237428 0.86 S1PR1 (0.42) S1PR1S1PR5S1PR3S1PR4OPRM1
SCHEMBL2238150 0.84 MCHR1 (0.50) OPRM1L3MBTL1KDM4EALDH1A1
SCHEMBL2314469 0.83 OPRM1 (0.46) S1PR1S1PR5S1PR3S1PR4OPRM1
SCHEMBL2315286 0.82 SMN1; SMN2 (0.45) OPRM1KMT2AHTTL3MBTL1LMNA
SCHEMBL2237167 0.82 OPRM1 (0.48) S1PR1S1PR5S1PR3S1PR4OPRM1
SCHEMBL2239987 0.82 OPRM1 (0.48) S1PR1S1PR5S1PR3S1PR4OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2011-08-18 US disclosed
EP-2331518-A1 NEW BRADYKININ B1 ANTAGONISTS Evotec AG (DE) 2011-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS BDKRB1, BDKRB2, BRS3 S1PR1 381/4885S1PR5 640/4885S1PR3 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.